FINNENCE ▪ THE WIRE FILE
THE WIRE · № 83970
News▲ Bullish
Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Positive CHMP opinion moves olezarsen toward EU approval, expanding the sHTG treatment market.
EU regulatory progress for a lipid-lowering drug
CATALYST TO WATCH
European Commission final approval decision
MAIN RISK
Pricing or reimbursement could disappoint
FULL DISPATCH
Positive CHMP opinion based on Phase 3 CORE and CORE2 results, demonstrating a statistically significant placebo-adjusted mean reduction of up to 72% in triglyceride levels and a significant 85% reduction in the rate of acute pancreatitis events with TRYNGOLZA (olezarsen) compared with...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development2026-10-16 11:30 UTC
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development2026-10-16 11:30 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. — AstraZeneca2026-10-16 12:00 UTC
New Phase 3 trial: A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. — AstraZeneca2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma — Nektar Therapeutics2026-10-16 12:00 UTC
Phase 3 results posted: NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma — Nektar Therapeutics2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin — Eli Lilly and Company2026-10-16 12:00 UTC
Phase 3 results posted: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin — Eli Lilly and Company2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis — Eli Lilly and Company2026-10-16 12:00 UTC
Phase 3 results posted: A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis — Eli Lilly and Company2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement2026-10-16 12:00 UTC
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement2026-10-16 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.